Antibody-based targeted therapy for gastric cancer
Open Access
- 25 November 2005
- journal article
- Published by Springer Science and Business Media LLC in Gastric Cancer
- Vol. 8 (4), 206-208
- https://doi.org/10.1007/s10120-005-0345-4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Bevacizumab—current status and future directionsAnnals Of Oncology, 2005
- Chemotherapy for advanced gastric cancerPublished by Wiley ,2005
- Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in CancerJournal of Clinical Oncology, 2005
- Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based TherapyJournal of Clinical Oncology, 2005
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients: a multivariate analysis using a standardized immunohistochemical detection systemLaboratory Investigation, 2004
- Expression of epidermal growth factor receptor in gastric carcinomasClinical Gastroenterology and Hepatology, 2003
- Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assayInternational Journal of Cancer, 2002
- Prognostic value of vascular endothelial growth factor expression in gastric carcinomaCancer, 1996